Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update

Article Abstract:

A nomogram that includes information about prostate-specific antigen (PSA) levels, Gleason score and clinical stage can predict whether prostate cancer is localized within the prostate and thus amenable to surgical treatment. Researchers used clinical and pathological data from 4,133 men with prostate cancer who had had their prostate removed. The earlier the stage of the tumor and the lower the Gleason score and PSA levels were, the more likely the tumor was confined to the prostate. Men with cancer confined to the prostate survive longer after treatment than those whose cancer has spread.

Analysis, Measurement, Physiological aspects, Tumor staging, Cancer staging

---

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

Article Abstract:

Men with an elevated prostate-specific antigen (PSA) level who have a free PSA level of 25% or less should have a prostate biopsy to detect prostate cancer. A PSA level greater than 4 is an indication that a man may have early prostate cancer. PSA is normally bound to other proteins in the blood but free PSA is not. Researchers used a cutoff of 25% free PSA to see if they could avoid unnecessary biopsies. A value of 25% or less detected 95% of cancers and avoided 20% of unnecessary biopsies. Men with a value of 25% or less were more likely to have prostate cancer.

Methods, Diagnosis, Medical screening, Health screening

---

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

Article Abstract:

The multicenter analysis of the outcome of salvage radiotherapy in a cohort of patients with recurrence of prostate cancer after radical prostatectomy is conducted for the identification of variables associated with a durable response. A durable response to salvage radiotherapy is achieved by patients with high-grade disease or a rapid prostate-specific antigen doubling time (PSADT).

United States, Science & research, Care and treatment, Research, Evaluation, Patient outcomes, Prostatectomy, Cancer patients, Radiotherapy, Cohort analysis, Outcome and process assessment (Health Care), Outcome and process assessment (Medical care)

Similar abstracts:

• Abstracts: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review
• Abstracts: A prion protein epitope selective for the pathologically misfolded conformation. The controversial protein-only hypothesis of prion propagation
• Abstracts: Court's rejection of assisted suicide leaves door ajar; ruling stresses need for better pain control in end-of-life care
• Abstracts: Do you have a strategy for handling managed care? How to better manage care by managing diseases
• Abstracts: Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.